B Group Inc. Buys Shares of 965,556 Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

B Group Inc. purchased a new position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 965,556 shares of the company’s stock, valued at approximately $1,670,000. Taysha Gene Therapies accounts for 1.0% of B Group Inc.’s holdings, making the stock its 10th biggest position. B Group Inc. owned approximately 0.47% of Taysha Gene Therapies at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. increased its stake in Taysha Gene Therapies by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 8,906,764 shares of the company’s stock worth $15,409,000 after purchasing an additional 641,305 shares during the period. Geode Capital Management LLC grew its holdings in shares of Taysha Gene Therapies by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 3,572,349 shares of the company’s stock worth $6,182,000 after purchasing an additional 9,591 shares during the last quarter. State Street Corp increased its stake in Taysha Gene Therapies by 4.5% in the 3rd quarter. State Street Corp now owns 3,469,068 shares of the company’s stock worth $6,973,000 after buying an additional 150,647 shares during the period. JPMorgan Chase & Co. lifted its holdings in Taysha Gene Therapies by 1.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,001,397 shares of the company’s stock valued at $6,033,000 after buying an additional 37,844 shares in the last quarter. Finally, Norges Bank purchased a new stake in Taysha Gene Therapies in the 4th quarter valued at about $2,528,000. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Stock Up 5.1 %

Taysha Gene Therapies stock opened at $1.24 on Monday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The firm has a market cap of $254.27 million, a P/E ratio of 1.97 and a beta of 0.96. The business has a fifty day moving average of $1.54 and a two-hundred day moving average of $1.81. Taysha Gene Therapies, Inc. has a twelve month low of $1.05 and a twelve month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. The firm had revenue of $2.02 million during the quarter, compared to analyst estimates of $2.05 million. On average, analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, April 10th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.